Related Experiment Video
Updated: Jun 17, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Emerging antiviral drugs for hepatitis C virus
Masaru Enomoto1, Akihiro Tamori, Norifumi Kawada
1Department of Hepatology, Osaka City University Medical School, Osaka, Japan.
Abstract:
Infection with hepatitis C virus (HCV) is a global health problem that affects approximately 170 million people worldwide. The current standard therapy with peginterferon alpha plus ribavirin for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1--the most prevalent type of HCV in North America and Europe. Development of new antiviral medicines has been hampered by the lack of an effective cell culture system and small-animal model. Herein we review recent progress in the development of new treatments under investigation in clinical trials, including specifically targeted antiviral therapy for HCV such as NS3/4A protease and NS5B polymerase inhibitors.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Inhibitors Of Virion Release

